Toggle search
Toggle menu
406
21
32
6.1K
Pharmacopedia
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Drilldown: Medicines

More actions

Choose a table:


Medicines > classes : Amphetamine or Neuroleptic or Research material

Use the filters below to narrow your results.

generic:
brand:
None (130) · (none, never marketed) (1) · Adderall, Adderall XR, Mydayis (1) · Captagon (1) · Clozaril (1) · Desoxyn (1) · Dexedrine (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · O-DSMT (1) · Orap (1) · Prolixin (1) · Saphris (1) · Stelazine (1) · Thorazine (1) · Trilafon (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) · Monoamine releasing agent (10) · GABAA positive allosteric modulator (8) · CB1/CB2 agonist (7) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Phenothiazine D2 antagonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Serotonin/norepinephrine/dopamine releasing agent (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2)
uses:
None (149) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"' (1) · '"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"' (1)
starting dose:
None (149) · 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis (1) · 5 mg PO (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)
preparations:
None (149) · Desoxyn 5 mg tabs (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) · IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1)
fda max:
None (149) · 25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label) (1) · N/A (never approved) (1) · XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"' (1)
routes:
None (149) · intranasal; rectal and IV reported. (1) · Oral (2) · Oral (prescribed) (1) · sublingual (1)
onset:
None (150) · IR: 30–60 min; XR: 1–2 h to peak effect (1) · ~20–40 min PO; faster sublingual/intranasal. (1)
duration:
None (150) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · IR 4–6 h; XR 10–12 h; Mydayis 14–16 h (1)
halflife:
None (150) · D-amphetamine ~10 h; L-amphetamine ~13 h (adults) (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1)
bioavailability:
None (150) · Not formally characterized in humans. (1) · ~75–90% (oral) (1)
pregnancy:
None (149) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Category C (1) · Category C (per Desoxyn label) (1)
legal:
None (150) · Schedule II (2)

Showing below up to 158 results in range #1 to #158.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"